1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 薬剤タイプ別スニペット
3.2. エンドユーザー別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 標的治療への嗜好の高まり
4.1.2. 阻害要因
4.1.2.1. 治療に伴う高コスト
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. アンメット・ニーズ
5.6. PESTEL分析
5.7. 特許分析
5.8. SWOT分析
6. 薬剤タイプ別
6.1. はじめに
6.1.1. 薬物タイプ別市場規模分析および前年比成長率分析（%） 6.1.2.
6.1.2. 市場魅力度指数（薬物タイプ別
6.2. 化学療法薬
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 標的薬
6.4. その他
7. エンドユーザー別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
7.1.2. 市場魅力度指数、エンドユーザー別
7.2. 病院*市場
7.2.1. はじめに
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 専門クリニック
7.4. その他
8. 競争環境
8.1. 競争シナリオ
8.2. 市場ポジショニング／シェア分析
8.3. M&A分析
9. 企業プロフィール
9.1. F. Hoffmann-La Roche Ltd *
9.1.1. 会社概要
9.1.2. 製品ポートフォリオと内容
9.1.3. 財務概要
9.1.4. 主な展開
9.2. Novartis Pharmaceuticals Corporation
9.3. Celltrion Inc.
9.4. Karyopharm
9.5. Gilead Sciences Inc.
9.6. MorphoSys AG
9.7. AbbVie Inc.
9.8. CTI BioPharma Corp
9.9. Seagen Inc.
9.10. TG Therapeutics Inc. (*リストは除外)
10. 付録
10.1. 会社概要とサービス
10.2. お問い合わせ
The North America diffuse large B-cell lymphoma therapeutics market reached US$ 2017.11 million in 2023 and is expected to reach US$ 3577.3 million by 2031, growing at a CAGR of 7.6% during the forecast period 2024-2031.
Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a type of blood cancer that affects white blood cells called lymphocytes. It is a cancer of the lymphatic system. Lymphoma develops when white blood cells called lymphocytes grow out of control. They move around the body in the blood and the lymphatic system. The lymphatic system is an important part of our immune system. It has tubes that branch through all parts of the body.
These tubes are called lymph vessels or lymphatic vessels and they carry a straw-coloured liquid called lymph. This liquid circulates around the body tissues. It contains a high number of white blood cells (lymphocytes) which fight infection. DLBCL develops when the body makes abnormal B lymphocytes. So it is a type of B cell lymphoma. The abnormal lymphocytes build up in the lymph nodes or other body organs. They don't work properly. So they can't fight infection as normal white blood cells do.
Market Dynamics: Drivers
Increasing preference for targeted therapies
The increasing preference for targeted therapies propels the market growth. Targeted therapy is one of the most widely preferred methods for the treatment of diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer. Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are among the targeted therapies used for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells. Ibrutinib is a targeted therapy that inhibits Bruton's tyrosine kinase pathway.
Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently.
Restraints
Factors such as the high cost associated with the treatment are expected to hamper the market. The high cost associated with the treatment of diffuse large B-cell lymphoma is expected to restrain the market growth to a certain extent, as this limits the number of individuals undergoing the treatment. The cost to treat diffuse large B-cell lymphoma (RR DLBCL) can be high and that’s only taking into account first- and second-line treatments that can cost as much as $200,000.
Segment Analysis
The North America diffuse large B-cell lymphoma therapeutics market is segmented based on drug type and region.
The segment chemotherapy drugs accounted for approximately 48.3% of the North America diffuse large B-cell lymphoma therapeutics market share
The chemotherapy drugs segment is expected to hold the largest market share over the forecast period. In this segment, the increase in approvals, and rising funds for private manufacturers for clinical trials would drive this market.
Diffuse large B-cell lymphoma (DLBCL) tends to grow quickly. Most often, the treatment is chemotherapy (chemo), usually with 4 drugs known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), plus the monoclonal antibody rituximab (Rituxan). This regimen, known as R-CHOP, is most often given in cycles 3 weeks apart. Other chemo regimens may be used instead for people with heart problems or other serious health issues.
First-line treatment options for these lymphomas include R-CHOP and Pola-R-CHP, which is a combination of the monoclonal antibodies polatuzumab vedotin and rituximab and the chemo drugs cyclophosphamide, doxorubicin, and prednisone. Other regimens that include chemo and rituximab might be options as well.
Market Segmentation
By Drug Type
Chemotherapy Drugs
Targeted Drugs
Rituximab
Polutuzumab vedotin-piiq
Pembrolizumab
Tisagenlecleucel
Ibrutinib
Others
By End-User
Hospitals
Specialty Clinics
Others
Competitive Landscape
The major players in the North America diffuse large B-cell lymphoma therapeutics market include F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals Corporation, Celltrion Inc., Karyopharm, Gilead Sciences Inc., MorphoSys AG, AbbVie Inc., CTI BioPharma Corp, Seagen Inc., TG Therapeutics Inc. among others.
Key Developments
In 2023, the FDA approved the first bispecific T-cell engager agents, epcoritamab-bysp and glofitamab-gxbm. These two agents constitute new third-line options for patients with relapsed or refractory DLBCL.
In June 2024, Pfizer Inc. announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study showed that the ADCETRIS combination reduced the patient’s risk of death by 37% compared to placebo in combination with lenalidomide and rituximab.
Why Purchase the Report?
To visualize the North America diffuse large B-cell lymphoma therapeutics
Market Segmentation based on drug type and end-user as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of North America diffuse large B-cell lymphoma therapeutics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The North America diffuse large B-cell lymphoma therapeutics market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by End-User
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Preference for Targeted Therapies
4.1.2. Restraints
4.1.2.1. High Cost Associated with the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Chemotherapy Drugs *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Targeted Drugs
6.4. Others
7. By End-User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Others
8. Competitive Landscape
8.1. Competitive Scenario
8.2. Market Positioning/Share Analysis
8.3. Mergers and Acquisitions Analysis
9. Company Profiles
9.1. F. Hoffmann-La Roche Ltd *
9.1.1. Company Overview
9.1.2. Product Portfolio and Description
9.1.3. Financial Overview
9.1.4. Key Developments
9.2. Novartis Pharmaceuticals Corporation
9.3. Celltrion Inc.
9.4. Karyopharm
9.5. Gilead Sciences Inc.
9.6. MorphoSys AG
9.7. AbbVie Inc.
9.8. CTI BioPharma Corp
9.9. Seagen Inc.
9.10. TG Therapeutics Inc. (*LIST NOT EXHAUSTIVE)
10. Appendix
10.1. About Us and Services
10.2. Contact Us
*** びまん性大細胞型B細胞リンパ腫治療薬の世界市場に関するよくある質問(FAQ) ***
・びまん性大細胞型B細胞リンパ腫治療薬の世界市場規模は？
→DataM Intelligence社は2023年のびまん性大細胞型B細胞リンパ腫治療薬の世界市場規模を20億1711万米ドルと推定しています。
・びまん性大細胞型B細胞リンパ腫治療薬の世界市場予測は？
→DataM Intelligence社は2031年のびまん性大細胞型B細胞リンパ腫治療薬の世界市場規模を35億7730万米ドルと予測しています。
・びまん性大細胞型B細胞リンパ腫治療薬市場の成長率は？
→DataM Intelligence社はびまん性大細胞型B細胞リンパ腫治療薬の世界市場が2024年～2031年に年平均7.6%成長すると展望しています。
・世界のびまん性大細胞型B細胞リンパ腫治療薬市場における主要プレイヤーは？
→「F. Hoffmann-La Roche Ltd.、Novartis Pharmaceuticals Corporation、Celltrion Inc.、Karyopharm、Gilead Sciences Inc.、MorphoSys AG、AbbVie Inc.、CTI BioPharma Corp.、Seagen Inc.、TG Therapeutics Inc.など ...」をびまん性大細胞型B細胞リンパ腫治療薬市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
